Table 3.
GO groups with significant enrichment, based on a comparison of the top-210 significant genes differentially expressed between metastases and primary tumours against all genes present on the microarray. The number of genes in the total list and observed and expected number of genes in the gene list that map to the GO group are shown. + or − signs indicate over- or underrepresentation, respectively, of this GO group. P-values were Bonferroni corrected for multiple testing, P-value < 0.05.
| GO group | # Genes total | Gene list | |||
|---|---|---|---|---|---|
| # Observed | # Expected | +/− | P-value | ||
| Biological process | |||||
| Immunity and defence | 1365 | 30 | 11.3 | + | 3.7E–5 |
| Granulocyte mediated immunity | 59 | 6 | 0.5 | + | 1.7E–3 |
| Macrophage mediated immunity | 126 | 8 | 1.1 | + | 1.8E–3 |
| Cell proliferation and differentiation | 944 | 20 | 7.8 | + | 4.2E–3 |
| Blood circulation and gas exchange | 82 | 5 | 0.7 | + | 2.0E–2 |
| Cell cycle control | 390 | 12 | 3.2 | + | 1.7E–2 |
| JNK cascade | 60 | 5 | 0.5 | + | 3.2E–2 |
|
| |||||
| Molecular function | |||||
| Surfactant | 9 | 5 | 0.7 | + | 2.8E–6 |
| Chemokine | 45 | 5 | 0.4 | + | 6.8E–3 |
| Interleukin | 34 | 4 | 0.3 | + | 4.1E–2 |